AR099303A1 - Construcciones de aptámeros - Google Patents
Construcciones de aptámerosInfo
- Publication number
- AR099303A1 AR099303A1 ARP150100345A ARP150100345A AR099303A1 AR 099303 A1 AR099303 A1 AR 099303A1 AR P150100345 A ARP150100345 A AR P150100345A AR P150100345 A ARP150100345 A AR P150100345A AR 099303 A1 AR099303 A1 AR 099303A1
- Authority
- AR
- Argentina
- Prior art keywords
- aptamer
- teranostic
- agent
- subject
- aptamer according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3511—Conjugate intercalating or cleaving agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Reivindicación 1: Un aptámero que comprende la secuencia 5-X-ACGUAUACUAU-Y-3 (SEQ ID Nº 1), donde las secuencias de X y de Y son complementarias y posibilitan el apareamiento entre las bases, y donde cada uno de X e Y comprende un extensión de nucleótidos de C y G apareados que es suficiente para posibilitar la unión de al menos una unidad. Reivindicación 23: Un aptámero de acuerdo con cualquier reivindicación precedente, que puede unirse de manera específica a las células CD133+. Reivindicación 27: Un agente de diagnóstico o teranóstico que comprende un aptámero de acuerdo con cualquier reivindicación precedente. Reivindicación 31: Un método para tratar un cáncer en un sujeto que lo necesita, que comprende administrarle al sujeto un aptámero de acuerdo con una cualquiera de las reivindicaciones 1 a 21 o un agente de teranóstico de acuerdo con la reivindicación 27 ó 28. Reivindicación 34: Una composición que comprende una cantidad eficaz para el uso terapéutico de un aptámero de acuerdo con una cualquiera de las reivindicaciones 1 a 21 o de un agente de teranóstico de acuerdo con la reivindicación 27 ó 28 en combinación con un vehiculo y/o un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014900347A AU2014900347A0 (en) | 2014-02-05 | Aptamer Construct |
Publications (1)
Publication Number | Publication Date |
---|---|
AR099303A1 true AR099303A1 (es) | 2016-07-13 |
Family
ID=53777070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150100345A AR099303A1 (es) | 2014-02-05 | 2015-02-06 | Construcciones de aptámeros |
Country Status (10)
Country | Link |
---|---|
US (1) | US10221420B2 (es) |
EP (1) | EP3102708B1 (es) |
JP (1) | JP6636436B2 (es) |
CN (1) | CN106164293B (es) |
AR (1) | AR099303A1 (es) |
AU (1) | AU2015213483B2 (es) |
CA (1) | CA2938776C (es) |
ES (1) | ES2851924T3 (es) |
SG (1) | SG11201606379UA (es) |
WO (1) | WO2015117201A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150233932A1 (en) * | 2013-02-19 | 2015-08-20 | Ching-Ping Tseng | Methods, Systems, and Compositions for Enrichment of Rare Cells |
US11008575B2 (en) * | 2015-07-28 | 2021-05-18 | The University Of North Carolina At Charlotte | DNA aptamers against cancer and uses thereof in delivery of therapy and diagnosis of cancer |
WO2017173247A1 (en) * | 2016-03-31 | 2017-10-05 | City Of Hope | Aptamer compositions and the use thereof |
CN105925687A (zh) * | 2016-05-15 | 2016-09-07 | 陈博 | 一种用于儿科的肺吸虫病诊断的试剂盒及其诊断方法 |
EP3332812A1 (en) * | 2016-12-07 | 2018-06-13 | Rheinische Friedrich-Wilhelms-Universität Bonn | Nucleic acid-based assembly and use of the assembly in cancer therapy |
WO2018207024A1 (en) * | 2017-05-08 | 2018-11-15 | Augmanity Nano Ltd | Treatment of rapidly evolving biological entities |
CN108866061A (zh) * | 2018-06-21 | 2018-11-23 | 中山大学附属第五医院 | 一种识别肝癌细胞的核酸适配体及其筛选方法与用途 |
JP2022513327A (ja) * | 2018-09-28 | 2022-02-07 | オーグマニティ ナノ リミテッド | 機能性アプタマーを選択するための方法および組成物 |
CN109536503B (zh) * | 2018-12-06 | 2021-03-02 | 浙江省肿瘤医院 | 一种靶向结合cd133蛋白的核酸适配体及其筛选方法和用途 |
CN109439665B (zh) * | 2018-12-06 | 2021-04-02 | 浙江省肿瘤医院 | 一种靶向结合cd133蛋白的核酸适配体药物偶联物及其用途 |
CN109536505B (zh) * | 2018-12-07 | 2021-11-09 | 暨南大学 | 鬼臼毒素的核酸适配体及其应用 |
KR102154683B1 (ko) * | 2019-11-08 | 2020-09-11 | 주식회사 압타머사이언스 | 글리피칸-3 특이적 변형 압타머 및 이의 용도 |
CN110904112B (zh) * | 2019-12-12 | 2024-04-02 | 福州市长乐区宝爱冬医学技术有限公司 | 一种白喉毒素的核酸适配体dt03及其应用 |
CN110885828B (zh) * | 2019-12-12 | 2024-04-05 | 方斌 | 一种白喉毒素的核酸适配体dt01及其应用 |
CN111505287B (zh) * | 2020-05-07 | 2023-04-07 | 军事科学院军事医学研究院军事兽医研究所 | 以乙醛脱氢酶作为信号转导系统检测食源性病原菌的生物传感器及其制备方法和应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6261774B1 (en) | 1990-06-11 | 2001-07-17 | Gilead Sciences, Inc. | Truncation selex method |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
WO1991019813A1 (en) | 1990-06-11 | 1991-12-26 | The University Of Colorado Foundation, Inc. | Nucleic acid ligands |
US6127119A (en) | 1990-06-11 | 2000-10-03 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
US6028186A (en) | 1991-06-10 | 2000-02-22 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of cytokines |
WO2000037932A2 (en) | 1998-12-23 | 2000-06-29 | Admetric Biochem Inc. | High throughput method for measuring physicochemical values |
US6171795B1 (en) | 1999-07-29 | 2001-01-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to CD40ligand |
EP1474450A2 (en) | 2002-02-08 | 2004-11-10 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | A novel target to inhibit angiogenesis |
GB0305422D0 (en) | 2003-03-10 | 2003-04-16 | Univ Open | Detection, monitoring and treatment of cancer |
US20060263336A1 (en) | 2003-03-24 | 2006-11-23 | Caplan Arnold I | Cell targeting methods and compositions |
IL179285A (en) | 2004-05-14 | 2011-04-28 | Rosetta Genomics Ltd | Micrornas and uses thereof |
JP4664298B2 (ja) | 2004-08-24 | 2011-04-06 | 富士フイルム株式会社 | 表面プラズモン共鳴分析における解離定数の算出方法 |
JP2008512098A (ja) * | 2004-09-07 | 2008-04-24 | アーケミックス コーポレイション | フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用 |
CA3218940A1 (en) | 2004-11-12 | 2006-05-18 | Cambridge University Technical Services Ltd. | Methods and means related to cancer stem cells |
JP5406534B2 (ja) * | 2006-03-08 | 2014-02-05 | アーケミックス エルエルシー | 補体結合アプタマーおよび眼障害の処置において有用な抗c5剤 |
US20110052697A1 (en) | 2006-05-17 | 2011-03-03 | Gwangju Institute Of Science & Technology | Aptamer-Directed Drug Delivery |
JP2007319153A (ja) | 2006-06-02 | 2007-12-13 | Takashi Otsu | 核酸リガンドと中和剤との組み合わせ製剤 |
US20090047295A1 (en) | 2007-07-12 | 2009-02-19 | Berry David A | Methods and Compositions for Reducing Stemness in Oncogenesis |
US20110206614A1 (en) | 2007-11-23 | 2011-08-25 | Whitehead Institute For Biomedical Research | Systemic instigation systems to study tumor growth or metastasis |
US20120045846A1 (en) | 2010-08-23 | 2012-02-23 | Avia Biosystems, Llc | SYSTEM AND METHOD FOR pH FORMULATIONS |
US9840712B2 (en) * | 2012-08-02 | 2017-12-12 | Deakin University | CD133 aptamers for detection of cancer stem cells |
-
2015
- 2015-02-05 JP JP2016550266A patent/JP6636436B2/ja active Active
- 2015-02-05 SG SG11201606379UA patent/SG11201606379UA/en unknown
- 2015-02-05 CN CN201580011915.5A patent/CN106164293B/zh not_active Expired - Fee Related
- 2015-02-05 WO PCT/AU2015/050039 patent/WO2015117201A1/en active Application Filing
- 2015-02-05 AU AU2015213483A patent/AU2015213483B2/en active Active
- 2015-02-05 US US15/117,164 patent/US10221420B2/en active Active
- 2015-02-05 EP EP15747052.7A patent/EP3102708B1/en active Active
- 2015-02-05 CA CA2938776A patent/CA2938776C/en active Active
- 2015-02-05 ES ES15747052T patent/ES2851924T3/es active Active
- 2015-02-06 AR ARP150100345A patent/AR099303A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN106164293A (zh) | 2016-11-23 |
CA2938776C (en) | 2023-08-22 |
SG11201606379UA (en) | 2016-09-29 |
WO2015117201A1 (en) | 2015-08-13 |
AU2015213483A1 (en) | 2016-08-18 |
EP3102708B1 (en) | 2020-11-18 |
US10221420B2 (en) | 2019-03-05 |
ES2851924T3 (es) | 2021-09-09 |
JP2017506074A (ja) | 2017-03-02 |
CA2938776A1 (en) | 2015-08-13 |
JP6636436B2 (ja) | 2020-01-29 |
EP3102708A1 (en) | 2016-12-14 |
AU2015213483B2 (en) | 2020-07-02 |
EP3102708A4 (en) | 2017-10-25 |
US20160355820A1 (en) | 2016-12-08 |
CN106164293B (zh) | 2020-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR099303A1 (es) | Construcciones de aptámeros | |
CL2022003763A1 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
CL2017000515A1 (es) | Cd123 agentes enlazadores y su uso | |
PH12018500714A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
MX2022010623A (es) | Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer. | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
PH12017500803A1 (en) | Anti-pd-1 antibodies | |
MD4733C1 (ro) | Anticorpi anti-TIGIT | |
UY35682A (es) | Anticuerpos anti-activina a y usos de los mismos | |
GEP20217328B (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
EA201790597A1 (ru) | Способы лечения вирусных инфекций filoviridae | |
MX2017008819A (es) | Anticuerpos anti-cd47 y usos de los mismos. | |
BR112015022625A2 (pt) | micromatrizes para entrega de agente terapêutico e métodos de uso | |
MD20150100A2 (ro) | Virusurile bolii de Newcastle şi utilizarea acestora | |
BR112016016916A2 (pt) | método de tratamento de angiodema hereditário (hae) | |
BR112015024234A2 (pt) | composição de liberação sustentada injetável e método para o uso da mesma para tratar inflamação em articulações e dor associada com a mesma | |
BR112017010761A2 (pt) | tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia | |
BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
BR112018006810A2 (pt) | regimes de dosagem | |
BR112018003928A2 (pt) | métodos para o tratamento de doenças | |
PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
EA201890623A1 (ru) | Рациональная комбинированная терапия для лечения рака | |
PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
CY1122708T1 (el) | Ενωσεις οξα-διαζασπειρο με δραση εναντι του πονου | |
WO2016145362A3 (en) | Inhibitors of dek protein and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |